Profiling platform-independent tumor classification using artificial intelligence

Affiliations

¹ Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria. claudia.manzl@i-med.ac.at.
² Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria. adelheid.woehrer@i-med.ac.at.

Claudia Manzl et al. Nat Cancer. 2025 Jul.

. 2025 Jul;6(7):1124-1125.

doi: 10.1038/s43018-025-00971-w.

¹ Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria. claudia.manzl@i-med.ac.at.
² Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria. adelheid.woehrer@i-med.ac.at.

No abstract available

Conflict of interest statement

Competing interests: The authors declare no competing interests.

1. Capper, D. et al. Nature 555, 469–474 (2018). - PubMed - PMC
1. Wu, Z. et al. Neuro. Oncol. 24, 571–581 (2021). - PMC
1. Heidelberg array methylation classifiers for CNS tumors, sarcoma and skin cancer; https://app.epignostix.com (accessed 29 January 2025).
1. Bethesda array methylation classifier for CNS tumors; https://methylscape.ccr.cancer.gov/ (accessed 29 January 2025).
1. Kuschel, L. P. et al. Neuropathol. Appl. Neurobiol. 49, e12856 (2023). - PubMed